VELPHORO Drug Patent Profile

When do Velphoro patents expire, and what generic alternatives are available?

Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and thirty-six patent family members in thirty-six countries.

The generic ingredient in VELPHORO is ferric oxyhydroxide. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ferric oxyhydroxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Velphoro

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 13, 2029. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VELPHORO

International Patents:	136
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	365
Drug Prices:	Drug price information for VELPHORO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELPHORO
What excipients (inactive ingredients) are in VELPHORO?	VELPHORO excipients list
DailyMed Link:	VELPHORO at DailyMed

See drug prices for VELPHORO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VELPHORO

NDA:

205109

Dosage:

TABLET, CHEWABLE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VELPHORO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Colorado, Denver	Phase 4
Prim. Priv. Doz. Dr. Daniel Cejka	Phase 2
Vifor Fresenius Medical Care Renal Pharma	Phase 2

See all VELPHORO clinical trials

Pharmacology for VELPHORO

Drug Class	Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity

US Patents and Regulatory Information for VELPHORO

VELPHORO is protected by eleven US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013		RX	Yes	Yes					Y

Expired US Patents for VELPHORO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vifor Fresenius	VELPHORO	ferric oxyhydroxide	TABLET, CHEWABLE;ORAL	205109-001	Nov 27, 2013

International Patents for VELPHORO

When does loss-of-exclusivity occur for VELPHORO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Philippines

Poland

Portugal

Russian Federation

Saudi Arabia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VELPHORO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014356500
Australia	2020217386
Australia	2022204380
Canada	2931173
China	105764492
Cyprus	1123956

Supplementary Protection Certificates for VELPHORO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0868125	C300710	Netherlands		PRODUCT NAME: MENGSEL VAN POLYNUCLEAIRE IJZER (III)-OXYHYDROXIDE, SUCROSE EN ZETMEEL; REGISTRATION NO/DATE: EU/1/14/943 20140826
0868125	PA2015003	Lithuania		PRODUCT NAME: POLICIKLINES GELEZIES (III) OKSIHIDROKSIDO, SACHAROZES IR KRAKMOLU MISINYS; REGISTRATION NO/DATE: EU/1/14/943/001 - EU/1/14/943/004 20140826
0868125	CA 2015 00007	Denmark		PRODUCT NAME: BLANDING AF POLYNUKLEAERT JERN(III)-OXYHYDROXID, SUCROSE OG STIVELSE; REG. NO/DATE: EU/1/14/943/001-004 20140826
0868125	15C0018	France		PRODUCT NAME: MELANGE D'OXYHYDROXYDE DE FER (III) POLYNUCLEAIRE,DE SACCHAROSE ET D'AMIDONS.; REGISTRATION NO/DATE: EU/1/14/943/001 20140826
0868125	C00868125/01	Switzerland		PRODUCT NAME: FERRIOXYHYDROXIDUM/SACCHARUM/AMYLA; REGISTRATION NO/DATE: SWISSMEDIC 62986 22.01.2015
0868125	425	Finland

VELPHORO (sucroferric oxyhydroxide) Market Dynamics and Financial Trajectory: Pricing, Uptake, Competition, and IP-Driven Risk

Last updated: July 23, 2026

VELPHORO (sucroferric oxyhydroxide) is a prescription ferric iron-based phosphate binder used for hyperphosphatemia in adults with chronic kidney disease (CKD) on dialysis. The market and financial trajectory are shaped by (1) payer coverage for non-calcium binders, (2) dialysis-market penetration through nephrology channels, (3) head-to-head tolerability and pill-burden dynamics versus lanthanum carbonate and sevelamer products, and (4) patent and regulatory timelines that determine how fast price competition can intensify.

What is VELPHORO and where does it fit in CKD hyperphosphatemia treatment?

Featured snippet answer: VELPHORO is a ferric oxyhydroxide-based phosphate binder for adults with CKD on dialysis with hyperphosphatemia, positioned as a non-calcium alternative intended to improve phosphate control while managing safety and dosing practicality.

How is VELPHORO typically used in dialysis patients?

• Indication: hyperphosphatemia in adults with CKD on dialysis.
• Role in treatment algorithms:
  • Often chosen when clinicians seek alternatives to calcium-based binders to manage calcium loading and vascular calcification risk.
  • Used in combination strategies with dietary phosphate restriction and, in many patients, vitamin D analogs or calcimimetics (depending on secondary hyperparathyroidism status).

What differentiates VELPHORO versus standard phosphate binders?

• Mechanism class: ferric-based binder (distinct from calcium salts, lanthanum, and polymeric resins).
• Key decision points in real-world adoption:
  • Serum phosphate reduction consistency.
  • Tolerability profile that affects adherence.
  • Practical dosing with meals and real patient pill/administration burden.
  • Gastrointestinal tolerability trade-offs relative to other non-calcium options.

What market dynamics drive uptake of ferric and non-calcium phosphate binders?

Featured snippet answer: Uptake is driven by payer restrictions and nephrology channel behavior, with non-calcium binders gaining share when calcium restriction policies tighten and when clinical teams prioritize tolerability and consistent phosphate control.

Payer coverage and formulary behavior: how do payers choose among binders?

Formulary dynamics for CKD on dialysis tend to follow:

• Step edits that require trial or documented failures of preferred binders.
• Automatic preferences where outcomes data and safety narratives align with payer risk models.
• Rebates and net-price concessions that determine the “effective” competitiveness more than list price.

For non-calcium binders, payer expectations often include:

• Demonstrated phosphate lowering with acceptable gastrointestinal tolerability.
• A risk narrative that avoids excess calcium exposure.
• Predictable maintenance dosing and adherence.

Nephrology prescribing patterns: what changes adoption most?

The dialysis population is highly protocolized through:

• Dialysis center formularies and standing orders.
• Standard-of-care pathways and nurse-driven medication management.
• Kidney care teams’ comfort with long-established products (sevelamer and lanthanum) versus newer entrants.

VE LPHORO’s adoption tends to depend on:

• Clinical confidence from label-consistent results.
• Site-level champions and education.
• Real-world persistence and pharmacy fill patterns (shaped by prior authorization and switching friction).

How does VELPHORO compare commercially with sevelamer and lanthanum?

Featured snippet answer: In the U.S. dialysis binder market, sevelamer and lanthanum dominate historical share, and VELPHORO must win through coverage access, perceived tolerability, and adherence practicality rather than unique clinical positioning alone.

Competitive set and market mechanics

1. Sevelamer (carbonate and hydrochloride)
   • Established in multiple lines of therapy and widely covered.
   • Strong familiarity in dialysis units.
2. Lanthanum carbonate
   • Another long-standing non-calcium option with payer-relevant pricing and coverage variability.
3. Calcium-based binders
   • Often lowest cost but increasingly constrained by calcium exposure policies.

Where does VELPHORO win share?

Typical win conditions for newer binders in dialysis include:

• Faster access on formularies through managed-care contracting.
• Clinician preference shifts driven by tolerability in subpopulations (patients with GI intolerance to polymers, or those managed with calcium avoidance).
• Switching from one non-calcium agent when phosphate targets are not met or adherence is impaired.

Where does VELPHORO lose share?

• When sevelamer or lanthanum are already preferred with minimal switching hurdles.
• When net-price after rebates makes incumbents effectively cheaper on payer contracts.
• When pill burden or meal-frequency expectations do not align with the dialysis unit’s medication administration workflow.

How does net price and payer contract pressure affect VELPHORO revenue?

Featured snippet answer: VELPHORO’s financial trajectory is likely to be more sensitive to contract rebates and formulary access than to changes in list price, because dialysis binder category margins depend heavily on payer contracting cycles.

Revenue drivers

• Patient starts: incremental use after coverage approval or formulary inclusion.
• Persistence: continuation without switch due to tolerability and phosphate control.
• Mix: how many patients are on VELPHORO monotherapy versus combination binder strategies.
• Contracting: rebate and access terms that determine realized revenue per patient.

Cost and margin considerations in specialty CKD

• Specialty distribution channels and administrative burden increase with prior authorization and switching.
• High competition in CKD binders tends to drive:
  • Rebates and market access spending.
  • Short contracting cycles and mid-year formulary changes.

What is the financial trajectory pattern for CKD phosphate binders like VELPHORO?

Featured snippet answer: Category entrants usually show an S-curve pattern: initial formulary-driven uptake, followed by slower growth or plateau unless payer coverage expands or competitive switching improves persistence.

Typical stage model for a dialysis binder entrant

• Launch and early adoption
  • Concentrated in centers with higher uptake propensity.
  • Sales and reimbursement resources target coverage pathways.
• Scaling
  • Growth depends on whether net coverage broadens beyond initial accounts.
  • Persistence data drive formulary confidence for expansion.
• Maturation and pressure
  • As incumbents intensify contracting, growth slows.
  • Margin compression follows if price concessions rise to maintain share.

What metrics best proxy VELPHORO’s financial trajectory?

Even without company-level disclosure here, market practitioners track:

• Prescriptions per covered life or per dialysis patient mix.
• Treatment duration and discontinuation rates (switching due to phosphate control or GI tolerability).
• Average selling price (ASP) trends net of rebates.
• Contract coverage expansion milestones.

How do patent and exclusivity timelines shape pricing power for VELPHORO?

Featured snippet answer: Pricing power in phosphate binders is constrained by patent estate scope and by how quickly generics or authorized competitors can enter after relevant protection expires.

What to watch in the VELPHORO patent and exclusivity stack

Market impact usually comes from:

• Orange Book-listed patents tied to the approved drug (formulation, composition, methods).
• Patent term extensions if applicable.
• Patent-specific litigation or settlements that can accelerate market entry risk.

How would generic entry affect revenues?

If meaningful generic competition occurs:

• Expect rapid formulary re-rating toward lower-cost binders.
• Higher switching rates for patients on non-calcium alternatives, particularly where clinical differences are modest.
• Revenue declines typically depend on:
  • How many contracts allow interchange.
  • How strong persistence is when clinical pathways still tolerate multiple binder options.

What generic entry risks exist for VELPHORO?

Featured snippet answer: Generic risk is determined by the strength and remaining term of Orange Book-protecting patents and whether paragraph IV challenges (if any) trigger early entry dates tied to litigation outcomes or settlements.

What a risk map looks like for phosphate binders

• Patent-protected formulation or composition: can block full generic entry until expiry.
• Method-of-use or dosing regimens: can delay some labeling substitutions.
• Litigation: can shift timing through court or settlement outcomes.
• Exclusivity: can create last-mile protection even if certain patents fall.

(Practical takeaway: revenue upside is most defensible when multiple independent patents cover core protected aspects of the drug and are near expiration only in the far end of the timeline.)

What FDA regulatory status factors affect commercial velocity?

Featured snippet answer: Label stability and any changes in FDA-approved dosing or safety language can affect payer comfort and clinician willingness to switch.

Pathway and label stability impact

• Stable indication and dosing simplifies formulary inclusion.
• Safety signal management impacts discontinuation risk.
• Any post-marketing safety communications can alter switching behavior even if efficacy is maintained.

What litigation and settlement events would change VELPHORO revenue forecasts?

Featured snippet answer: Any litigation over Orange Book patents, or settlements that allow “at-risk” or earlier-than-expected entry, is the highest-impact event for revenue forecasting in mature specialty markets.

What matters commercially in phosphate binder IP disputes

• Court findings on patent validity or infringement.
• Settlement terms on launch timing and potential scope of generic labeling.
• Whether “carve-outs” allow partial entry (for example, different strengths or delivery formats).

Key commercial scenarios for VELPHORO over the next 3-7 years

Featured snippet answer: The trajectory depends on whether VELPHORO expands payer coverage and maintains persistence, versus whether it faces accelerated generic competitive pressure from IP expiry or adverse litigation outcomes.

Scenario 1: Coverage expansion with stable competitive pricing

• Net revenue grows primarily through incremental patient starts and improved persistence.
• Margin pressure exists but is moderated by stable exclusivity and managed-care contracting.

Scenario 2: Plateau from incumbents re-contracting

• Growth slows as sevelamer/lanthanum remain entrenched in dialysis center formularies.
• VELPHORO maintains share only if it sustains favorable rebates.

Scenario 3: Accelerated pricing pressure from early competition

• If protection weakens or entry is timed earlier than expected, contracts shift quickly.
• Discontinuation rates rise; switching away accelerates.

Key Takeaways

• VELPHORO’s commercial trajectory is driven by dialysis formulary access, payer contracting economics, and persistence tied to tolerability and phosphate control.
• The competitive backdrop is dominated by sevelamer and lanthanum; VELPHORO must win through coverage and patient handling practicalities rather than broad category “new class” switching alone.
• The biggest revenue inflection risks come from the Orange Book patent estate durability and any litigation or settlement that accelerates generic competition.
• Financial outcomes should be modeled around three variables: patient starts, persistence/switching, and realized net price after rebates and formulary positioning.

FAQs

1) What payer coverage hurdles typically slow phosphate binder launches like VELPHORO?
Coverage delays often stem from step therapy, prior authorization, and formulary preferences that require documented failure or intolerance of established non-calcium agents.

2) How does tolerability influence switching between VELPHORO and sevelamer in real-world dialysis care?
GI tolerability and patient adherence patterns drive persistence. If tolerability profiles differ meaningfully for a subpopulation, centers may switch at the margin even under similar efficacy outcomes.

3) What Orange Book patents matter most for phosphate binders’ long-term revenue protection?
Patents covering composition/formulation and core protected aspects tied to the approved product typically matter most, as they restrict true generic substitution and interchange.

4) What are the main financial risks if VELPHORO faces earlier-than-expected competition?
The risks are rapid net-price compression from rebate escalation and high switching rates as dialysis centers move to lower-cost alternatives once interchange barriers fall.

5) How should investors benchmark VELPHORO’s performance against the category?
Track prescription growth, persistence/discontinuation, and net revenue per treated patient versus category peers, then overlay patent milestone timing for forward risk-adjusted forecasting.

References

No sources were cited because no verifiable, specific market size, revenue, patent listing, or exclusivity/litigation data for VELPHORO was provided in the input.

DrugChatter Q&A for VELPHORO

Para 4 challenge to velphoro patents?
Velphoro patient assistance program?
Velphoro price philippines?
Velphoro cost without insurance?
Velphoro mercury drug price?